Full Description
This comprehensive volume offers an in-depth exploration of dermatologic therapeutics, encompassing both foundational principles and the latest advancements in the field. Each drug is presented with a clear and concise overview, covering its introduction, mechanism of action, pharmacokinetics, indications, contraindications, clinical applications, adverse effects, and considerations for use during pregnancy, lactation, and in geriatric and pediatric populations.
Designed as an essential resource for clinicians, researchers, and students, the book provides a thorough understanding of both systemic and topical therapies in dermatology. Besides, it features detailed discussions on retinoids, biological immunomodulators and immunosuppressive agents—core components of modern dermatologic treatment. Enhanced with numerous flow diagrams and tables the book effectively illustrates key concepts and therapeutic pathways, offering readers a clear and structured perspective on clinical decision-making in dermatology. This is volume 1 of the set of three volumes.
Contents
Section I Antimicrobial drugs.- Chapter 1 Penicillins.- Chapter 2 Cefalosporins.- Chapter 3 Quinolones.- Chapter 4 Macrolides.- Chapter 5 Tetracyclines.- Chapter 6 Clindamycin.- Chapter 7 Metronidazole.- Chapter 8 Rifampicin.- Chapter 9 Vancomycin.- Chapter 10 Newer antimicrobials.- Section II Antiviral drugs.- Chapter 11 Acyclovir and Valacyclovir.- Chapter 12 Famciclovir.- Chapter 13 Cidofovir.- Chapter 14 Foscarnet.- Section III Antifungal drugs.- Chapter 15 Azoles.- Chapter 16 Terbenafine.- Chapter 17 Griseofulvin.- Chapter 18 Amphotericin B.- Chapter 19 5-Flucytosine.- Chapter 20 Echinocandins.- Chapter 21 Nikkomycin Z.- Section IV Systemic steroids.- Chapter 22 Systemic glucocorticorticoids.- Chapter 23 Steroid pulses in dermatology.- Section V Immunosuppressive drugs.- Chapter 24 Cyclophosphamide.- Chapter 25 Cyclosporine.- Chapter 26 Methotrexate.- Chapter 27 Azathioprine.- Chapter 28 Mycophenolate mofetil.- Chapter 29 Hydroxyurea.- Section VI Oral retinoids.- Chapter 30 Isotretinoin.- Chapter 31 Acitretin.- Chapter 32 Alitretinoin.- Chapter 33 Bexarotene.- Section VII Biologic immunomodulators.- Chapter 34 TNF alpha antagonists.- Chapter 35 Ustekinumab.- Chapter 36 IL-17 antagonists.- Chapter 37 IL-23 antagonists.- Chapter 38 Dupilumab.- Chapter 39 Omalizumab.- Chapter 40 Rituximab.- Chapter 41 Anakinra.
